EF001 免責聲明 | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 永勝醫療控股有限公司 | | 股份代號 | 01612 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至2025年6月30日止六個月之中期股息 | | 公告日期 | 2025年8月20日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 中期（半年期） | | 股息性質 | 普通股息 | | 財政年末 | 2025年12月31日 | | 宣派股息的報告期末 | 2025年6月30日 | | 宣派股息 | 每 股 0.024 HKD | | 股東批准日期 | 不適用 | | 香港過戶登記處相關信息 | | | 派息金額及公司預設派發貨幣 | 每 股 0.024 HKD | | 匯率 | 1 HKD : 1 HK ...

格隆汇8月6日丨永胜医疗(01612.HK)宣布，公司将于2025年8月20日（星期三）举行董事会会议，藉以 （其中包括）考虑及批准公司及其附属公司截至2025年6月30日止六个月的中期业绩、刊发有关中期业 绩以及派付中期股息（如有）。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01612 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 653,336,332 | | 0 | | 653,336,332 | | 增加 / 減少 (-) | | | 0 | | | | | | 本月底結存 | | | 653,336,332 | | 0 | | 653,336,332 | 公司名稱: 永勝醫療控股有限公司 呈交日期: 2025年8月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上 ...

Group 1: Market Overview - The Hang Seng Index fell by 1.11%, down 284 points, closing at 25,383 points, while the Hang Seng Tech Index dropped by 1.69% [1] - The early trading volume in Hong Kong stocks reached 151 billion HKD [1] Group 2: Medical Sector - Medical device stocks rose in early trading, with the national drug procurement policy indicating a move away from internal competition, leading institutions to view this as a turning point for the industry [1] - Aikang Medical (01789) increased by 7.93%, and Weigao Group (01066) rose by 4.37% [1] - Yongsheng Medical (01612) saw a surge of over 27% following a profit warning, with sales orders increasing and expected mid-term net profit growth exceeding 50% year-on-year [2] - CRO concept stocks continued to rise, with Citigroup noting that the CXO sector is gaining market attention ahead of earnings season [2] - Kanglong Chemical (300759) (03759) rose by 8.4%, while Zhaoyan New Drug (603127) (06127) increased by 5.7%, and WuXi Biologics (02269) rose by 4.5% [2] Group 3: Consumer Sector - Nongfu Spring (09633) increased by over 3.56%, reaching a three-and-a-half-year high, with institutions expecting the company's first-half revenue growth to exceed market expectations [3] Group 4: Other Notable Stocks - Jihong Co., Ltd. (002803) (02603) rose by 16%, with two main business segments performing well, and expected first-half net profit growth of up to 65% [4] - China Merchants Port (01199) increased by over 4%, following reports that China Merchants Group plans to acquire assets from Cheung Kong Ports [5] - Guichuang Tongqiao (02190) rose by 2.6%, with expected mid-term net profit growth of 66.9%, as the company embraces procurement and actively expands overseas [6] Group 5: Lithium and Duty-Free Sector - News of supply disruptions in the lithium market led to Tianqi Lithium (002466) (09696) rising by 3.6% [7] - China Duty Free Group (601888) (01880) fell by over 6%, with pending details on Hainan's duty-free policies, and institutions noting that the closure operations have a dual impact on offshore duty-free business [7] Group 6: Technology Sector - Qianxun Technology (01640) fell by over 3%, having retreated 23% from its previous high, with recent comments from Yu Weiwen emphasizing the need to avoid excessive speculation on stablecoins [8]

Summary of Key Points Core Viewpoint - As of July 14, a total of 138 stocks reached their 52-week highs, indicating a strong performance in the market, with notable leaders including Green Heart Group Holdings, OK Blockchain, and Pearl River Steel Pipe [1]. Group 1: Top Performers - Green Heart Group Holdings (02999) achieved a closing price of 0.013 with a peak of 0.017, marking a 70.00% increase [1]. - OK Blockchain (01499) closed at 0.680, reaching a high of 0.690, reflecting a 48.39% rise [1]. - Pearl River Steel Pipe (01938) had a closing price of 0.335 and a peak of 0.340, resulting in a 33.33% increase [1]. Group 2: Other Notable Stocks - Weishi Jiajie (00856) saw a 32.01% increase, closing at 8.870 with a high of 11.300 [1]. - Cloud Intelligence (09678) reached a high of 520.000, closing at 510.000, which is a 20.99% increase [1]. - China Chengtong Development Group (00217) closed at 0.165 with a peak of 0.166, marking a 14.48% rise [1]. Group 3: Additional Stocks with Significant Increases - Sihuan Pharmaceutical (00460) closed at 1.380, reaching a high of 1.430, which is a 14.40% increase [1]. - Taited Pharmaceutical (03880) had a closing price of 36.950 and a peak of 37.400, reflecting a 13.85% rise [1]. - Beihai Kangcheng-B (01228) closed at 0.850 with a high of 0.960, resulting in a 12.94% increase [1].

Market Overview - The Hang Seng Index fell by 0.45%, down 107 points, closing at 23,808 points, while the Hang Seng Tech Index decreased by 0.15% [1] - Early trading volume in Hong Kong stocks reached HKD 109.5 billion [1] Stablecoin Regulation - The Hong Kong Monetary Authority plans to release guidelines for stablecoin regulations this month, aiming to issue licenses within the year [1] - Stocks related to stablecoins saw significant gains, with Guotai Junan International rising by 8.2%, ZhongAn Online increasing by 5.64%, and Yike rising over 9% [1] New Tea Beverage Market - A subsidy war in the takeaway market has ignited the new tea beverage sector, with Guming and Cha Baidao both rising over 9% [1] Digital Health Services - Health Road saw its stock rise over 9% as its controlling shareholder voluntarily extended the lock-up period, focusing on a digital health service platform [1] Gaming Industry - Morgan Stanley reported that Macau's gaming revenue in June increased by 19% year-on-year to MOP 21.1 billion, exceeding analyst predictions by 9% [1] - Gaming stocks continued their upward trend, with Amax Holdings up 3.7%, Melco International Development up 1.6%, and MGM China up 2.1% [1] Medical Device Sector - In response to China's reciprocal restrictions on EU medical devices, the National Medical Products Administration issued support for high-end medical devices [1] - Medical device stocks experienced broad gains, with Spring Medical up 1.86%, Yongsheng Medical up 7.27%, and Xinwei Medical-B up 5.5% [1] Company Developments - China Rare Earth Holdings plans to spin off its gold business for independent listing on the Hong Kong Stock Exchange, potentially seeking financing before the spin-off [2] - Jihong Co. saw its stock rise over 10%, with a projected over 55% year-on-year increase in net profit attributable to shareholders for the first half of the year [3] - H&H International Holdings is expected to see a decline in net profit by 45% to 65% for the first half of the year, resulting in a drop of over 6% in its stock price [4]

Market Overview - The US stock market was closed on July 4th for Independence Day [1] Hong Kong Stock Market Highlights - Yum China (09987) rose over 3% after announcing the establishment of an innovation fund to convert operational needs into practical applications [2] - H&H International Holdings (01112) fell over 7%, expecting a 45% to 65% decline in net profit for the first half of the year [2] - China Rare Earth Holdings (03788) surged nearly 9% as it plans to spin off its gold business for independent listing on the Hong Kong Stock Exchange, potentially seeking financing before the spin-off [2] - Health Road (02587) jumped over 18% as its controlling shareholder voluntarily extended the lock-up period, focusing on digital health services [2] - Smoore International (06969) increased over 5% with the launch of Glo Hilo in Japan, maintaining high profit margins [2] - Tencent Music (01698) rose nearly 3% as institutions noted that recent acquisition plans would enhance overall content supply [2] - Jihong Co., Ltd. (02603) surged over 7%, with a projected net profit increase of over 55% year-on-year for the first half [2] - Solar stocks collectively declined, with Xinyi Solar (00968) down 4.86%, Fuyao Glass (06865) down 3.88%, New Energy (01799) down 3.19%, and Xinyi Glass (00868) down 2.64% [2] Other Notable Movements - Kuaishou-W (01024) rose over 3% as it plans to launch a live streaming initiative across multiple cities to create a collaborative ecosystem [3] - Gold stocks faced pressure, with Shandong Gold (01787) down 5.09%, China Gold International (02099) down 3.44%, Lingbao Gold (03330) down 2.68%, and Chifeng Jilong Gold (06693) down 2.33% [3] - China Shipbuilding Defense (00317) increased over 3% after the approval of a merger and acquisition restructuring plan, optimizing resources in the shipbuilding industry [3] - Medical device stocks saw a broad increase, with Spring Medical (01858) up 6.36%, Yongsheng Medical (01612) up 7.27%, Xinwei Medical-B (06609) up 3.55%, and Microneuroscience (02172) up 1.12% [3] - Some stablecoin concept stocks rose, with Victory Securities (08540) up 6.9%, Guotai Junan International (01788) up 5.15%, Yika (09923) up 2.59%, and China Everbright Holdings (00165) up 1.96% [3] - SF Express City (09699) rose nearly 7% amid intensified competition in the food delivery sector, with expectations of increased order volume [3] - HSSP International (03626) fell over 20% after being named by the Hong Kong Securities and Futures Commission for high stock concentration [3] Strategic Partnerships and New Listings - Shengye (06069) opened nearly 15% higher after forming a strategic partnership with Stand Robot to enhance its robotics industry chain [4] - Beverage stocks opened high, with Cha Bai Dao (02555) up 15%, Nayuki's Tea (02150) up 9.87%, Gu Ming (01364) up 5.77%, Hu Shang Ayi (02589) up 2.99%, and Mixue Group (02097) up 2.92% [4] - FWD Group (01828) had a flat opening on its first day of listing, being a life insurance company under Li Zeqiang's control [4]

Core Insights - The National Medical Products Administration (NMPA) has announced measures to optimize the lifecycle regulation of high-end medical devices, focusing on areas such as medical robots, high-end medical imaging equipment, AI medical devices, and new biological materials [1] - The global high-end medical device market is projected to exceed $1.8 trillion by 2030, with China's market expected to reach 2.8 trillion RMB [1] Industry Focus Areas - **Brain-Computer Interface (BCI)**: The BCI market in China is expected to reach 3.2 billion RMB in 2024, growing at 18.8%, and is projected to reach 5.58 billion RMB by 2027 with a growth rate of 20%. Challenges include technical bottlenecks and ethical controversies [2] - **High-End Medical Imaging Equipment**: The domestic market has seen rapid development, with increasing localization in mid-to-low-end products. However, high-end imaging equipment still faces challenges, particularly in the localization of key components [2] - **Surgical Robots**: The market for surgical robots is dominated by laparoscopic surgical robots, with the Da Vinci system currently leading. Domestic products are entering the market, which may disrupt the current landscape [3] - **High-Value Consumables**: These account for about 20% of the medical device market. While some segments have achieved domestic substitution, others, particularly in cardiac and neurological devices, still rely heavily on imports [3] - **In Vitro Diagnostics (IVD)**: The IVD industry has seen significant domestic advancement in low-end technologies, but high-end segments remain largely dominated by foreign brands [3] Market Trends - The medical device industry is characterized by a dual focus on technology-driven innovation and domestic substitution. Key components for high-end devices are being developed domestically, with some products nearing international standards [4] Related Companies - **MicroPort Scientific Corporation (微创机器人)**: Reported over 130 core product orders, with significant growth in laparoscopic surgical robots [5] - **Yimai Sunshine (一脉阳光)**: Engaged in building medical imaging centers and has launched an AI medical imaging model, marking a transition in the industry [6] - **Yongsheng Medical (永胜医疗)**: Focuses on rehabilitation robotics and has secured agreements for health care product procurement [6] - **Kangji Medical (康基医疗)**: Recently received regulatory approval for a four-arm laparoscopic surgical robot, expanding its clinical application range [7]

Financial Performance - The company reported a revenue of HKD 1.2 billion for the fiscal year 2024, representing a 15% increase compared to the previous year[7]. - Revenue for the year ended December 31, 2024, increased by 11.6% to HKD 800.963 million, compared to HKD 717.973 million in 2023[12]. - Total revenue for the year reached HKD 801.0 million, an increase of 11.6% compared to HKD 718.0 million in 2023, driven by increased orders in the imaging disposable products segment and growth in health care and wellness products[35]. - Profit attributable to owners increased by 20.8% to HKD 69.167 million, compared to HKD 57.275 million in 2023[12]. - Basic earnings per share increased to HKD 10.75 from HKD 8.87 in 2023[12]. - Total dividend per share for 2024 is HKD 3.30, up from HKD 2.75 in 2023[20]. - The company reported a net profit margin of 12%, up from 10% in the previous year, indicating improved operational efficiency[7]. User Growth and Market Expansion - User data showed a growth of 25% in active users, reaching 500,000 by the end of 2024[7]. - The company is expanding its market presence in Southeast Asia, targeting a 30% market share in the region by 2026[7]. Product Development and Innovation - New product launches included a state-of-the-art medical device that is expected to generate an additional HKD 200 million in revenue in 2025[7]. - Research and development expenses increased by 20%, totaling HKD 150 million, to support innovation and new technology[7]. - The company continues to invest in product quality control and compliance, having passed FDA reviews and received EU MDR certification for several respiratory medical devices[25]. - The company has a dedicated R&D department located in Dongguan, focusing on innovative and reliable medical technologies[84]. Strategic Initiatives - The company completed an acquisition of a competitor for HKD 300 million, enhancing its product portfolio and market reach[7]. - The company plans to accelerate digitalization, automation, and operational optimization, with new production facilities expected to commence trial operations by the end of 2025[34]. - The focus will remain on diversified growth strategies, particularly in imaging disposable products and respiratory products, while exploring AI opportunities in rehabilitation and healthcare products[23]. Financial Management and Capital Expenditure - Capital expenditure for the year was HKD 142.4 million, significantly up from HKD 21.3 million in 2023, mainly for the construction of new production facilities[44]. - The company had unutilized bank financing of HKD 487.0 million as of December 31, 2024, compared to HKD 93.9 million in 2023[54]. - Total interest-bearing borrowings rose to HKD 80.2 million from HKD 21.0 million in 2023, primarily to fund new production facilities[53]. Governance and Management - The company has a robust governance structure with independent directors overseeing compensation and audit committees, ensuring transparency and accountability[72]. - The board includes independent directors with over 40 years of experience in medical device management, marketing, and R&D, ensuring diverse expertise[73]. - The company’s executive team includes members with extensive backgrounds in biomedical engineering and risk management, enhancing operational oversight[67][69]. Risk Management - The company faces significant risks from global economic conditions, including trade protectionism, currency fluctuations, and geopolitical tensions, which may impact financial performance[87]. - Labor shortages and rising labor costs have become a challenge, potentially affecting the company's operational capacity[91]. - The company is subject to stringent regulatory requirements in the medical device industry, and changes in laws or regulations could hinder its ability to operate effectively[94]. Shareholder Engagement and Dividends - The proposed final dividend for the year ending December 31, 2024, is HKD 0.017 per share, an increase from HKD 0.015 in 2023[108]. - The company aims to distribute a total dividend of no less than 30% of the consolidated profit attributable to shareholders for each financial year[109]. Corporate Social Responsibility - The board of directors emphasized a commitment to environmental, social, and governance (ESG) initiatives, with a budget of HKD 50 million allocated for sustainability projects in 2025[7]. - The group made charitable donations of RMB 130,000 in the current year, compared to zero in 2023[119]. Employee Welfare and Culture - Employee welfare is prioritized through competitive compensation, benefits, and professional training programs[103]. - The company emphasizes a culture of integrity and ethical standards across all business activities, with training provided to employees[185].

Group 1: Regulatory Developments - The National Medical Products Administration (NMPA) is seeking public opinion on measures to optimize lifecycle regulation supporting high-end medical device innovation [1] - The draft emphasizes strengthening standards to lead innovation and improving the high-end medical device standard system [1] - Accelerated publication of standards for medical exoskeleton robots and radioactive nuclide imaging devices is planned [1] Group 2: Industry Trends - AI in healthcare is highlighted as a significant innovation direction, enhancing medical device functionality and clinical decision-making [1] - Companies are expected to leverage AI to improve product competitiveness and customer loyalty, solidifying their market position [1] Group 3: Company Performance - MicroPort Robotics (02252) is experiencing strong order trends, with sales contribution from robotics expected to rise from approximately 3% in 2024 to about 40% by 2033 [2] - Yimaitong (02522) is advancing in medical imaging services and has launched an AI company that released a global first full-modal medical imaging model [2] - Yongsheng Medical (01612) reported a revenue of approximately HKD 801 million for 2024, a year-on-year increase of 11.6%, driven by increased orders in imaging disposable products [3] - Kangji Medical (09997) is set to launch its surgical robot business, with significant investments in its subsidiary Weijing Medical, which has completed clinical trials for its four-arm surgical robot system [4]